In addition to the observed effects on CRC genes and FOXM1/E2F/DREAM complex core genes, the drug synergism also effects TP53 pathway response (Fig. 8e), in keeping which the finding that TP53 activation may sensitize transcriptionally addicted cancer cells to THZ1 inhibition44. Here, TP53 is linked to colorectal carcinoma.